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Introduction: Lung cancer and chronic obstructive pulmonary disease 
(COPD) share environmental risk factors. COPD also increases the 
risk of lung cancer; however, the molecular mechanisms are unclear.
Methods: An epigenome-wide association study of lung tumors and 
cancer-free lung tissue (CFLT) pairs from non–small-cell lung cancer 
cases with (n = 18) or without (n = 17) COPD was conducted using 
the HumanMethylation450 beadchip (HM450K). COPD-associated 
methylation of top-ranked genes was confirmed in a larger sample 
set, independently validated, and their potential as sputum-based bio-
markers was investigated.
Results: Methylation of CCDC37 and MAP1B was more prevalent in 
lung tumors from COPD than non-COPD cases [54 of 71 (76%) versus 
20 of 46 (43%), p = 0.0013] and [48 of 71 (68%) versus 17 of 46 (37%), 
p = 0.0035], respectively, after adjustment for age, sex, smoking status, 
and tumor histology. HM450K probes across CCDC37 and MAP1B 
promoters showed higher methylation in tumors than CFLT with the 
highest methylation seen in tumors from COPD cases (p < 0.05). These 
results were independently validated using The Cancer Genome Atlas 
data. CCDC37 methylation was more prevalent in sputum from COPD 
than non-COPD smokers (p < 0.005) from two cohorts. CCDC37 and 
MAP1B expression was dramatically repressed in tumors and CFLT 
from COPD than non-COPD cases, p less than 0.02.
Conclusions: The reduced expression of CCDC37 and MAP1B asso-
ciated with COPD likely predisposes these genes to methylation that 
in turn, may contribute to lung cancer.
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(J Thorac Oncol. 2015;10: 1181–1188)
Lung cancer and chronic obstructive pulmonary disease (COPD) are the leading causes of morbidity and mortal-
ity worldwide.1 In the United States, COPD is the third major 
cause of death next to cardiovascular and malignant diseases, 
while lung cancer is the largest cause of cancer mortality, 
being responsible for approximately a third of all cancer-
related deaths.2 In addition to sharing similar etiology, as 
cigarette smoking is the major risk factor for both diseases, 
multiple epidemiological studies have consistently demon-
strated a strong link between COPD and lung cancer (recently 
reviewed by Houghton3). The presence of COPD increases the 
risk of lung cancer by twofold to fourfold suggesting that the 
pathogenesis of the two diseases may also follow similar path-
ways.4,5 The enormous human life and economic loss associ-
ated with these diseases and the lack of effective treatment for 
both have increasingly attracted intensive research. However, 
the molecular mechanisms by which COPD contributes to 
lung cancer development remain largely uncharacterized.3
Epigenetic silencing of genes through histone modifica-
tions and methylation of cytosines in promoter regions affects 
the expression of hundreds of genes and is a major causal 
event during lung cancer development.6,7 The commonality and 
involvement of gene methylation in carcinogenesis together 
with the development of sensitive methylation assays have led 
to studies focused on establishing the utility of methylation as 
a biomarker in screening for cancer risk, prevention, treatment, 
and prognosis. Our group was the first to establish that cancer 
associated methylation of genes could be detected in sputum 
samples from high-risk smokers before clinical diagnosis of 
lung cancer risk.8,9 We have also evaluated the commonality 
of aberrant methylation of candidate genes in COPD and lung 
cancer. Methylation analysis of a panel of eight lung cancer-
related genes in sputum DNA from 1267 cancer-free smokers 
showed that methylation of p16 (CDKN2A) and GATA4 was 
significantly associated with lower lung function.10 Similarly, 
Suzuki et al.11 used a candidate gene approach to identify that 
the genetic and epigenetic profile of lung tumors from COPD 
patients was distinct from that of non-COPD cases. These 
findings suggest that the development of COPD through cig-
arette smoke induced DNA damage, and remodeling drives 
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the epigenetic silencing of cell growth-related genes, which 
could, in turn, contribute to the development of lung cancer. 
Identification of these abnormalities in sputum samples from 
smokers with COPD may provide new biomarkers for COPD 
development and progression, and early cancer detection.
Thus, the objective of this study was to conduct an epig-
enome-wide association study (EWAS) to compare the methyla-
tion changes across the whole genome of lung tumor–normal pairs 
from non–small-cell lung cancer (NSCLC) patients with or with-
out COPD. The EWAS was performed using the HM450K that 
generates methylation data for over 480,000 CpGs genome-wide. 
For this study, we focused on approximately 160,000 probes that 
are located within CpG islands in gene promoter regions (TSS 
1500 as defined by Bibikova et al.12), excluding regions normally 
regulated by methylation, such as imprinted and X-chromosome 
genes. Methylation of the identified genes was confirmed in 
larger sample sets using different methylation assays, and the 
results were independently validated using HM450K data from 
The Cancer Genome Atlas (TCGA) database. Expression of 
selected genes was quantified in lung tumor–normal pairs, and 
the relationship between methylation and expression was evalu-
ated. Finally, the utility of detecting methylated genes in sputum 
for potential development of noninvasive biomarkers for COPD 
was investigated in two geographically distinct cohorts.
MATERIALS AND METHODS
Study Subjects, COPD Status, and Samples
Frozen lung tumor samples from 117 NSCLC patients (71 
with and 46 without COPD) were obtained from tumor banks at 
the University of New Mexico and the Mayo Clinic. Only tumors 
with ≥75% tumor purity were considered suitable for study. For 
a subset of these cases, cancer-free lung tissues (CFLT) collected 
from sites most distant to the tumor in the resected lobe were 
evaluated along with the tumor pair. COPD status and sever-
ity were defined according to the Global Initiative for Chronic 
Obstructive Lung Disease classification.13 Sputum samples from 
two longitudinal smoker cohorts, the Lovelace Smokers cohort 
(LSC, participants from the Albuquerque, NM metropolitan 
area since 200114–17) and the Pittsburgh Lung Screening Study 
(PLuSS, established in 200218), were studied. Characteristics of 
subjects whose tissue/sputum samples were studied are shown 
in Tables 1 and 2. Normal human bronchial epithelial cells col-
lected from 10 cancer-free smokers at University of New Mexico 
through diagnostic bronchoscopy9 and peripheral blood mono-
nuclear cells (PBMC) obtained from 10 healthy donors were 
used as normal control. All samples were obtained with written 
informed consent from patients, and the study was approved by 
each institute’s Ethics Committee. In addition, five human bron-
chial epithelial cell lines and five human small airway epithe-
lial cell lines immortalized as described,19 and 23 NSCLC cell 
lines were also studied. The cell lines used in this study and their 
sources, authentications, and handling methods are described 
in the Supplementary material (Supplemental Digital Content, 
http://links.lww.com/JTO/A849).
DNA Methylation and Gene Expression Analysis
DNA extraction, modification, and methylation analy-
sis using Combined Bisulfite Modification and Restriction 
TABLE 1.   Characteristics of Patients Whose Lung Samples Were Used in This Study
Characteristics
COPD Non-COPD
Total 
(n = 71)
Discovery 
(n = 18)
Total 
(n = 46)
Discovery 
(n = 17)
Sex (F) 31 (44%) 8 (44%) 24 (52%) 11 (65%)
Age, median ± SD (range) 65 ± 8.4 (48–80) 65 ± 9.0 (48–78) 65 ± 8.0 (49–80) 65 ± 9.0 (49–78)
Smoking status: smokers (current)a 15 (21%) 5 (28%) 7 (15%) 2 (12%)
Lung cancer
  Stage IA–IB 40 (56%) 12 (67%) 20 (43%) 8 (47%)
  Stage IIA–IIB 13 (18%) 2 (11%) 9 (20%) 4 (24%)
  Stage IIIA–IIIB 12 (17%) 3 (17%) 13 (28%) 5 (29%)
  Stage IV 7 (10%) 1 (6%) 4 (9%) 0 (0%)
Histology
  Adenocarcinoma (AC) 35 (49%) 18 (100%) 32 (70%) 17 (100%)
  Squamous cell carcinoma (SCC) 36 (51%) 0 (0%) 14 (30%) 0 (0%)
  Cancer-free lung tissue (CFLT) 9 3 8 3
COPD status (based on post-FEV1)
  Non-COPD (FEV1/FVC ≥ 70%) 0 (0%) 0 (0%) 46 (100%) 17 (100%)
COPD severity (FEV1/FVC < 0.70) and
  GOLD 1 (FEV1 ≥ 80% predicted); mild 4 (6%) 1 (6%) 0 (0%) 0 (0%)
  GOLD 2 (50% ≤ FEV1 < 80%); moderate 41 (58%) 8 (44%) 0 (0%) 0 (0%)
  GOLD 3 (30% ≤ FEV1 <50%); severe 25 (35%) 8 (44%) 0 (0%) 0 (0%)
  GOLD 4 (FEV1 <30%); very severe 1 (1%) 1 (6%) 0 (0%) 0 (0%)
aAll samples are from smokers.
COPD, chronic obstructive pulmonary disease; FEV, forced expiratory volume, FVC, forced vital capacity; GOLD, global initiative for chronic obstructive lung disease.
Copyright © 2015 by the International Association for the Study of Lung Cancer
1183Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 8, August 2015  CCDC37 and MAP1B Repression Links COPD to Lung Cancer
Analysis (CoBRA), Methylation-Specific polymerase chain 
reaction (MSP), and (for sputum samples) nested MSP assays 
were conducted as described.20–22 The primer sequences and 
amplification conditions are shown in Supplementary Tables 
1 and 2 (Supplemental Digital Content, http://links.lww.com/
JTO/A849). Genome-wide methylation of lung tumor–normal 
pairs was quantified using HM450K (Illumina, San Diego, 
CA).12 Methylation data for lung tumor–normal pairs evaluated 
by TCGA was obtained from https://tcga-data.nci.nih.gov/tcga/.
Gene expression analysis was conducted using RNA iso-
lated from lung tumor–CFLT pairs and cell lines as described.23 
Briefly, 1 μg total RNA was reverse transcribed using the 
high capacity cDNA Reverse Transcription Kit from Applied 
Biosystems (Foster City, CA) according to the manufacturer’s 
protocol. Expression of CCDC37, MAP1B, and BETA-ACTIN 
was quantified using Hs00403623_m1, Hs00195485_m1, and 
4310881E TaqMan assays (Applied Biosystems), respectively, as 
described.24,25 All samples were analyzed at least twice in dupli-
cate, and expression levels were calculated using the real time 
quantitative analysis, ΔΔCT method.26
Statistical Analysis
Gene methylation and patient characteristics including 
age, sex, smoking, COPD status, and tumor histology were 
summarized with mean and standard deviation for continuous 
variables and proportions for categorical variables. HM450K 
data for lung tumors from COPD and non-COPD cases were 
compared using β-regression analysis.27 The association 
between methylation and patient characteristics was assessed 
by Fisher’s exact test. Gene expression levels were compared 
using two-tailed T-test for unequal variance (COPD versus 
non-COPD cases) and pairwise T-test (tumor versus normal 
pairs). All analyses were conducted in SAS 9.2 and R 2.14.
RESULTS
Genome-Wide Screening of Cytosine 
Methylation in Lung Tumor–Normal Pairs
Tumors from 18 COPD and 17 non-COPD lung adeno-
carcinoma cases along with six CFLT pairs (three COPDs and 
three non-COPDs) and PBMC from three cancer-free donors 
were screened for methylation using HM450K. A total of 138 
probes within 43 genes showed significantly higher methyla-
tion in lung tumors from COPD compared with non-COPD 
cases. Exclusion of probes with features (shown in Fig. 1) 
suggesting limited biomarker and/or gene-silencing poten-
tial narrowed the candidates to 108 probes within 30 genes. 
Methylation of these 30 genes was evaluated by CoBRA and 
MSP assays using PBMC from cancer-free smokers (n = 5) 
and NSCLC cell lines (n = 23). Based on the CoBRA/MSP 
results, six genes that were methylated in PBMC and eight 
genes that were rarely (<5%) methylated in NSCLC cell lines 
were excluded. The final 16 genes, which were verified by 
CoBRA/MSP for showing methylation in ≥2 NSCLC cell 
lines but not in PBMC, were evaluated by MSP using the 
same lung tumor–CFLT pairs interrogated by HM450K. The 
prevalence for methylation of 10 of the 16 genes was increased 
by ≥15% in tumors from COPD compared with non-COPD 
cases (Supplementary Table 3, Supplemental Digital Content, 
http://links.lww.com/JTO/A849). Methylation of these 10 
genes was then evaluated in the remaining tumor–CFLT 
pairs, and the aggregate results are summarized in Table 3. 
After adjustment for age, sex, smoking status, and tumor his-
tology, lung tumors from COPD cases showed significantly 
higher prevalence for methylation of CCDC37 and MAP1B 
(p < 0.005). CCDC37 was methylated in 54 of 71 (76%) 
lung tumors from COPD compared with 20 of 46 (43%) 
non-COPD cases, while MAP1B was methylated in 48 of 71 
(68%) tumors with COPD versus 17 of 46 (37%) non-COPD 
subjects. Methylation of the remaining eight genes was not 
significantly different between lung tumors from COPD and 
non-COPD cases.
Independent Quantitative Validation 
of CCDC37 and MAP1B methylation
The level of methylation across CCDC37 and MAP1B 
promoters was quantified using HM450K. The locations of 
eight CCDC37 and six MAP1B probes with respect to the pro-
moter CpG island and first exon of each gene are depicted in 
TABLE 2.   Characteristics of Cancer-free Smokers Whose Sputum Samples Were Studied
Characteristics
LSC Cohort, n (%)a PLuSS Cohort, n (%)a
COPD 
(n = 100)
Non-COPD 
(n = 111)
COPD 
(n = 102)
Non-COPD 
(n = 103)
Sex (F) 72 (72%) 79 (71%) 64 (63%) 72 (70%)
Age, median + SD (range) 64 ± 8.3 (41–80) 63 ± 8.1 (41–76) 65 ± 5.4 (63–80) 64 ± 5.2 (52–80)
Smoking status: smokers (current)b 48 (48%) 56 (50%) 64 (63%) 56 (54%)
COPD status (based on post-FEV1)
  Non-COPD (FEV1/FVC ≥ 70%) 0 (0%) 111 (100%) 0 (0%) 103 (100%)
COPD: FEV1/FVC < 0.70 and
  GOLD 1 (FEV1 ≥ 80% predicted) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
  GOLD 2 (50% ≤ FEV1 < 80%) 63 (63%) 0 (0%) 48 (47%) 0 (0%)
  GOLD 3 (30% ≤ FEV1 < 50%) 31 (31%) 0 (0%) 42 (41%) 0 (0%)
  GOLD 4 (FEV1 < 30%) 6 (6%) 0 (0%) 12 (12%) 0 (0%)
aLovelace Smokers cohort (LSC) from the Albuquerque, New Mexico metropolitan area since 2001, Pittsburgh Lung Screening Study (PLuSS) cohort established in 2002.
bAll samples are from smokers.
COPD, chronic obstructive pulmonary disease; FEV, forced expiratory volume, FVC, forced vital capacity; GOLD, global initiative for chronic obstructive lung disease.
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X-axes of Figures 2 and 3. Comparison of these probes using 
our HM450K data for normal lung and tumors from COPD 
and non-COPD cases revealed that methylation of all eight 
CCDC37 probes was significantly increased in lung tumors 
compared with normal lung (p < 0.05). Each probe showed 
the highest methylation in tumors from COPD cases includ-
ing four probes (*φ) with significantly higher methylation in 
tumors from COPD than non-COPD subjects (Fig. 2A). Using 
β ≥ 0.2 as a cutoff to define hypermethylation, the prevalence 
for aberrant methylation of each probe was also increased 
significantly from normal lung to tumors in non-COPD 
cases and further increased in tumors from COPD cases 
(Supplementary Table 4, Supplemental Digital Content, http://
links.lww.com/JTO/A849). These results were independently 
validated using the TCGA data that were similarly generated 
by HM450K from a separate lung cancer cohort. TCGA data 
for 10 normal lung tissue and 61 lung tumors from NSCLC 
cases whose spirometry data were available and met with 
our classification criteria of COPD (n = 17) or non-COPD 
(n = 44) were analyzed. Characteristics of patients whose sam-
ples were evaluated by TCGA and the data used in this study 
are shown in Supplementary Table 5 (Supplemental Digital 
Content, http://links.lww.com/JTO/A849). With the exception 
of probe cg20952286, which is missing for all TCGA sam-
ples, the level and prevalence for methylation of the remain-
ing seven CCDC37 probes was similar to our data (Fig. 2B, 
Supplementary Table 6, Supplemental Digital Content, http://
links.lww.com/JTO/A849). The identical results supported 
a combined analysis of the TCGA and our data sets, which 
revealed that the prevalence and level of methylation of all 
seven CCDC37 probes were significantly higher in lung tumors 
from COPD than non-COPD cases (Fig. 2C, Supplementary 
Table 7, Supplemental Digital Content, http://links.lww.
com/JTO/A849). Similarly, quantitative analysis of all six 
MAP1B probes using our samples (Fig. 3A, Supplementary 
Table 4, Supplemental Digital Content, http://links.lww.com/
JTO/A849), TCGA data (Fig. 3B, Supplementary Table 6, 
Supplemental Digital Content, http://links.lww.com/JTO/
A849), and combined analysis of the two data sets (Fig. 3C, 
Supplementary Table 7, Supplemental Digital Content, http://
links.lww.com/JTO/A849) also showed the lowest methyla-
tion in normal lung that was significantly increased in lung 
tumors from COPD cases and to a lesser extent in tumors 
from non-COPD cases. However, unlike CCDC37, the higher 
methylation of each MAP1B probe in COPD than non-COPD 
tumors was not statistically significant.
Methylation of CCDC37 and MAP1B in Sputum
The potential use of CCDC37 and MAP1B methylation 
as noninvasive biomarkers for COPD was evaluated using 
FIGURE 1.  Strategy to identify aberrantly hypermethylated 
genes linking chronic obstructive pulmonary disease (COPD) 
to lung cancer (n = genes, probes).
TABLE 3.   Prevalence for Methylation of Genes in Lung Tumors and Cancer-Free Lung Tissue (CFLT) Pairs from NSCLC patients 
with or without COPD
Genes
Methylation, n (%)
Fisher Exact Testa 
(P Values)
COPD Non-COPD
CFLT 
(n = 22)
Tumor 
(n = 71)
CFLT 
(n = 11)
Tumor 
(n = 46)
CCDC37b 4 (18) 54 (76) 1 (9) 20 (43) 0.0013
CCDC67 1 (5) 26 (37) 1 (9) 10 (22) 0.1490
CDK5R2 0 (0) 13 (18) 0 (0) 11 (24) 0.6342
COCH 0 (0) 14 (20) 0 (0) 5 (11) 0.3064
GLB1L3 7 (32) 30 (42) 0 (0) 12 (26) 0.1157
MAP1Bb 5 (23) 48 (68) 2 (18) 17 (37) 0.0035
STOX2 8 (36) 51 (72) 6 (55) 29 (63) 0.5363
WNT9B 2 (9) 23 (32) 1 (9) 9 (20) 0.1301
ZNF132 1 (5) 25 (35) 1 (9) 10 (22) 0.0988
ZNF167 3 (14) 19 (27) 0 (0) 11 (24) 0.6655
aP values for tumors after adjustment for age, sex, smoking status, and tumor histology.
bPromoter CpG islands with significantly more prevalent methylation in lung tumors from COPD than non-COPD cases.
COPD, chronic obstructive pulmonary disease; NSCLC, non–small-cell lung cancer.
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sputum samples from cancer-free smokers with or without 
COPD. The prevalence for methylation of CCDC37 in spu-
tum samples from LSC cohort was 60% (60 of 100) in COPD 
cases compared with 36% (40 of 111) in control (Table 4). 
After adjustment for age, sex, and smoking status, methylation 
FIGURE 2.  Quantitative methylation analysis of CCDC37 pro-
moter CpG islands. The HM450K array probes cg23816347, 
cg09686643, cg01815671, cg11229862, cg20952286, 
cg20312228, cg21109744, and cg00891278 interrogate 
the methylation levels across the promoter CpG island of 
CCDC37 (~200 bp) targeting CpGs within the first exon and 
its upstream region. The methylation level (β-value) of each 
probe could range from β = 0 (no methylation) to  
β = 1 (100% methylation). Methylation was compared 
between normal lung and lung tumors from chronic obstruc-
tive pulmonary disease (COPD) and non-COPD cases using 
(A) our data, (B) The Cancer Genome Atlas (TCGA) data, and 
(C) a combination of the two data sets. The results are shown 
as mean ± standard deviation (SD) of β-values. The methyla-
tion levels among normal lung tissues were similarly low while 
tumors from both COPD and non-COPD cases showed large 
variation (depicted by the large SD). Details of the methyla-
tion analysis including the range and prevalence for methyla-
tion of each probe are shown in Supplementary Tables 4, 6, 
and 7 (Supplemental Digital Content, http://links.lww.com/
JTO/A849). Each probe IDs on the x-axes is shortened by 
replacing the first six numbers following cg by a hyphen (-).
FIGURE 3.  Quantitative methylation analysis of MAP1B pro-
moter CpG islands. The methylation levels of HM450K probes 
cg16478236, cg02001410, cg26001333, cg15412498, 
cg07380496, and cg02606808 that target CpGs across the 
promoter CpG island of MAP1B were compared between 
normal lung and lung tumors from chronic obstructive 
pulmonary disease (COPD) and non-COPD cases using (A) 
our data, (B) The Cancer Genome Atlas (TCGA) data, and (C) 
a combination of the two data sets. The analysis was done 
exactly as described for Figure 2 and the statistical details 
including the range and prevalence for methylation are 
shown in Supplementary Tables 4, 6, and 7 (Supplemental 
Digital Content, http://links.lww.com/JTO/A849).
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of CCDC37 in the sputum of COPD cases was significantly 
higher than control, odds ratio (OR), 2.74 and 95% confidence 
interval (95% CI), 1.55–4.90 (p = 0.0006). This result was 
independently validated using sputum samples from the geo-
graphically distinct PLuSS cohort, where CCDC37 methyla-
tion was highly prevalent in COPD cases than controls, OR, 
2.79; 95% CI, 1.37–5.66 (p = 0.0046). A combined analysis 
of the two cohorts also confirmed that CCDC37 was more fre-
quently methylated in the sputum of COPD cases than con-
trols, OR, 2.55; 95% CI, 1.68–3.87 (p < 0.0001; Table 4). In 
contrast, the prevalence for MAP1B methylation in sputum 
samples from the LSC cohort was similar between COPD 
cases (24%, 24 of 100) and controls (23%, 25 of 111), OR, 
1.10; 95% CI, 0.58–2.08 (p = 0.78) and thus was not analyzed 
in PLuSS samples.
CCDC37 and MAP1B Expression 
in COPD and Lung Cancer
Quantitative analysis of CCDC37 and MAP1B tran-
scripts in lung tumor–CFLT pairs from adenocarcinoma 
patients revealed that CFLT from COPD cases expressed 
significantly lower levels of both genes compared with CFLT 
from non-COPD cases, p = 0.020 and 0.010, respectively 
(Fig. 4A and B). Similarly, lung tumors from COPD cases 
expressed significantly lower CCDC37 and MAP1B than 
tumors from non-COPD cases, p = 0.010 and 0.003, respec-
tively (Fig. 4C and D). Comparison of CCDC37 expression 
between lung tumors and CFLT pairs within COPD or non-
COPD cases separately also revealed significant repression in 
tumors of either group (Fig. 4E). In contrast, MAP1B expres-
sion in lung tumors from COPD or non-COPD cases was 
similar to the CFLT pairs in the corresponding COPD group, 
likely reflecting the heterogeneity for expression between cell 
types comprising the normal tissue (Fig. 4F).
DISCUSSION
This EWAS identified that epigenetic mediated repres-
sion of CCDC37 and MAP1B is significantly associated with 
COPD and lung cancer. The dramatic reduction in expres-
sion of these genes is initiated in the cancer-free COPD lung. 
Expression is further reduced or maintained at lower levels 
in lung tumors from COPD cases with accompanying pro-
moter hypermethylation. Together, these findings fit with 
Clark and Melki’s28 model that states methylation in cancer 
is a consequence rather than the cause of gene silencing. 
Hence, repression of these genes in COPD before lung can-
cer is likely predisposing for the increased methylation dur-
ing lung carcinogenesis and may contribute to the increased 
risk of lung cancer observed in COPD patients. Moreover, 
CCDC37 methylation was more prevalent in the sputum of 
cancer-free smokers with than without COPD. This finding, 
which was independently validated in a geographically dis-
tinct cohort, supports CCDC37 silencing by methylation as 
an early event linked with COPD before cancer development. 
Although aberrant methylation of CCDC37 in lung cancer and 
MAP1B in colorectal cancer has been previously reported,29,30 
this is the first study to link these epigenetic changes to COPD 
and lung cancer.
Epigenetic modifications are key molecular mecha-
nisms that allow cells to regulate gene expression networks 
in response to environmental stimuli.31 Cigarette smoke, the 
major risk factor for lung cancer and COPD, is an example of 
such environmental stimuli.3 Our previous studies have dem-
onstrated that in vitro exposure of human bronchial epithelial 
cell lines to tobacco carcinogens initially repress expression 
of genes and microRNAs through histone modifications (such 
as deacetylation, methylation, and/or demethylation), which 
create a closed chromatin structure repressive to transcrip-
tion.7 Long-term epigenetic silencing of such repressed genes 
occurs during malignant transformation through hypermeth-
ylation of the promoter CpG islands. Studies from our group 
and others have shown that genes with constitutively lower 
expression and promoter activity are more prone to becoming 
methylated during cancer development within that organ.28,32 
These prior findings and concepts seem operative for regulat-
ing expression of CCDC37 and MAP1B during the develop-
ment of COPD and lung cancer.
CCDC37 is one of a large family of genes encoding for 
coiled-coil domain containing (CCDC) proteins. Currently, 
there is no publication regarding the function of CCDC37. 
However, Yamamoto et al.33 recently demonstrated that MAI1, 
a homologue of CCDC37 in Chlamydomonas reinhardtii, a 
single celled chlorophyte (green algae), is an essential regula-
tor of ciliary motility and speculated that CCDC37 might have 
similar function in humans and other higher organisms. Cilia 
motility plays a key role in clearing mucous from the lungs 
and is severely reduced in the COPD patient. Accumulating 
TABLE 4.   Prevalence for Methylation of CCDC37 and MAP1B Promoter CpG Islands in Sputum Samples from COPD Cases 
and Controls
Genes Cohortsa
Methylation n (%) Logistic Regressionb
Cases Controls Odds Ratio (95% CI) P Value
CCDC37 LSC 60/100 (60) 40/111 (36) 2.74 (1.55–4.90) 0.0006
PLuSS 86/103 (83) 66/107 (64) 2.79 (1.37–5.66) 0.0046
Combined 146/203 (72) 106/218 (49) 2.55 (1.68–3.87) < 0.0001
MAP1B LSC 24/100 (24) 25/111 (23) 1.10 (0.58–2.08) 0.78
aLovelace smokers cohort (LSC) and (PLuSS) cohort from the Pittsburgh Lung SPORE.
bAdjusted for age, sex, and smoking status.
COPD, chronic obstructive pulmonary disease; CI, confidence interval.
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mucous will result in increased pulmonary inflammation 
and likely enhanced oxidative damage to DNA that in turn 
could play a role in further gene silencing through promoter 
hypermethylation.17,34
MAP1B encodes for microtubule-associated protein 
1B (MAP1B), one of the major cytoskeletal proteins that is 
involved in various cellular activities including actin-based 
cell motility, molecular trafficking, autophagy, and cancer.35–37 
This large (2464 amino acids) protein is first synthesized as 
a polyprotein precursor, which is rapidly cleaved to give rise 
to the respective heavy and light chains, termed MAP1B-HC 
and MAP1B-LC1.38 Previous studies have demonstrated that 
MAP1B-LC1 interacts with Pes1 and p53 to modulate cell 
proliferation and apoptosis.39,40 Thus, loss of function of this 
gene may contribute to the cancer cell’s ability evade death 
signals and proliferate. Together, silencing of CCDC37 and 
MAP1B during development of COPD may contribute to the 
development of malignant NSCLC.
Our group has been instrumental in demonstrating and 
validating aberrant methylation of genes in sputum samples 
from high-risk smokers as a molecular marker for predicting 
lung-cancer risk.8,9 We and others have also reported that detec-
tion of methylation in sputum samples could link lung cancer 
with other risk factors such as smoking and COPD.10,20,41,42 The 
dramatic repression of CCDC37 in CFLT from COPD cases, 
its further repression by methylation in lung cancer, and the 
significant association of its methylation in sputum samples 
from cancer-free smokers with COPD support its potential 
as a biomarker for lung-cancer risk in COPD patients. Thus, 
future studies should investigate if adding this novel biomarker 
to previously identified biomarker panels10,43 will improve the 
sensitivity and specificity of predicting lung-cancer risk among 
COPD patients. Functional assays evaluating the mechanism by 
which epigenetic silencing of these genes contribute to COPD 
and lung cancer could provide additional insight into the molec-
ular link between these two major public health hazards.
FIGURE 4. CCDC37 and MAP1B 
expression in lung tumor-normal 
pairs. Expression of (A) CCDC37 and 
(B) MAP1B in cancer-free lung tissue 
(CFLT) from chronic obstructive 
pulmonary disease (COPD) cases 
was significantly repressed than CFLT 
from non-COPD cases. C and D, 
Similarly, expression of both genes in 
lung tumors from COPD cases was 
significantly lower than tumors from 
non-COPD cases. E, While CCDC37 
expression in lung tumors was sig-
nificantly reduced than CFLT pairs in 
both COPD and non-COPD groups, 
(F) MAP1B expression was not sig-
nificantly changed between tumors 
and CFLT pairs in either COPD or 
non-COPD cases.
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